Last $6.41 USD
Change Today +0.25 / 4.06%
Volume 5.8M
CERS On Other Exchanges
CERS is not on other exchanges.
As of 5:20 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

cerus corp (CERS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $8.00
52 Week Low
07/28/14 - $3.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CERUS CORP (CERS)

cerus corp (CERS) Related Bloomberg News

View More Bloomberg News

cerus corp (CERS) Related Businessweek News

No Related Businessweek News Found

cerus corp (CERS) Details

Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

115 Employees
Last Reported Date: 03/7/14
Founded in 1991

cerus corp (CERS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $495.8K
Co-Founder, Chief Medical Officer, Chief Scie...
Total Annual Compensation: $398.2K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $277.0K
President of Cerus Europe and EEMEA
Total Annual Compensation: $304.4K
Senior Vice President of Regulatory Affairs, ...
Total Annual Compensation: $315.4K
Compensation as of Fiscal Year 2013.

cerus corp (CERS) Key Developments

Cerus Corporation - Special Call

To discuss the U.S. approval for INTERCEPT platelets

FDA Approves INTERCEPT Blood System for Platelets

Cerus Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for platelets. The INTERCEPT platelet system is approved for ex vivo preparation of pathogen-reduced apheresis platelet components in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD). The approval marks the first time that a system to inactivate pathogens in platelet components will be available in the United States. The FDA approved the INTERCEPT Blood System for plasma on December 16. The INTERCEPT systems for both plasma and platelets use the same illumination device, the same active compound (amotosalen) and very similar production steps.

Cerus Corporation - Special Call

To discuss the US approval for INTERCEPT plasma


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERS:US $6.41 USD +0.25

CERS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.63 USD +0.03
AtriCure Inc $19.24 USD -0.03
Biolase Inc $2.65 USD -0.03
STAAR Surgical Co $9.10 USD -0.12
SurModics Inc $21.49 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation CERS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.8x
Price/Book 10.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERUS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at